Literature DB >> 18668575

Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis.

Joel Rosenbloom1, Sergio A Jiménez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18668575      PMCID： PMC2746747          DOI： 10.1002/art.23634

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  22 in total

Review 1.  Role of transforming growth factor beta in human disease.

Authors:  G C Blobe; W P Schiemann; H F Lodish
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.

Authors:  Yuka Hirose; Hitoshi Kiyoi; Masanori Iwai; Toshiya Yokozawa; Masafumi Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 3.  Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.

Authors:  Sergio A Jimenez; Chris T Derk
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

4.  Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

Authors:  Hitoshi Yoshiji; Ryuichi Noguchi; Shigeki Kuriyama; Yasuhide Ikenaka; Junichi Yoshii; Koji Yanase; Tadashi Namisaki; Mitsuteru Kitade; Tsutomu Masaki; Hiroshi Fukui
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-12-23       Impact factor: 4.052

5.  Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.

Authors:  Christine Beham-Schmid; Ute Apfelbeck; Heinz Sill; Oleksiy Tsybrovsky; Gerald Höfler; Oskar A Haas; Werner Linkesch
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

6.  ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.

Authors:  Robert P Hasserjian; Federica Boecklin; Sally Parker; Andy Chase; Sunanda Dhar; Michael Zaiac; Eduardo Olavarria; Irvin Lampert; Kristin Henry; Jane F Apperley; John M Goldman
Journal:  Am J Clin Pathol       Date:  2002-03       Impact factor: 2.493

Review 7.  Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Authors:  John Varga; David Abraham
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 8.  TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.

Authors:  Bernhard Schmierer; Caroline S Hill
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

Review 9.  TGF-beta signaling: a tale of two responses.

Authors:  Rod A Rahimi; Edward B Leof
Journal:  J Cell Biochem       Date:  2007-10-15       Impact factor: 4.429

Review 10.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962
View more
  10 in total

Review 1.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

2.  Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Authors:  Sonsoles Piera-Velazquez; Alma Makul; Sergio A Jiménez
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

3.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 4.  Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis.

Authors:  Francesco Del Galdo; Michael P Lisanti; Sergio A Jimenez
Journal:  Curr Opin Rheumatol       Date:  2008-11       Impact factor: 5.006

5.  A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.

Authors:  S Bhattacharyya; W Ishida; M Wu; M Wilkes; Y Mori; M Hinchcliff; E Leof; J Varga
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

Review 6.  Transforming growth factor beta as a therapeutic target in systemic sclerosis.

Authors:  John Varga; Boris Pasche
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

Review 7.  Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.

Authors:  Mohammed A Omair; Abdulaziz Alahmadi; Sindhu R Johnson
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

8.  Treatment effects of the traditional Chinese medicine Shenks in bleomycin-induced lung fibrosis through regulation of TGF-beta/Smad3 signaling and oxidative stress.

Authors:  Haiyan Chu; Ying Shi; Shuai Jiang; Qicheng Zhong; Yongqiang Zhao; Qingmei Liu; Yanyun Ma; Xiangguang Shi; Weifeng Ding; Xiaodong Zhou; Jimin Cui; Li Jin; Gang Guo; Jiucun Wang
Journal:  Sci Rep       Date:  2017-05-22       Impact factor: 4.379

9.  Comparative Evaluation of SMAD-2 Expression in Oral Submucous Fibrosis and Reactive Oral Lesions.

Authors:  Sravya Zagabathina; Ramya Ramadoss; Harini Priya Ah; Rajkumar Krishnan
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

Review 10.  Microvascular targets for anti-fibrotic therapeutics.

Authors:  Kai-Ming T Pu; Parid Sava; Anjelica L Gonzalez
Journal:  Yale J Biol Med       Date:  2013-12-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.